提交付款方申诉

Most ECD treatments are still considered off-label treatments, meaning it often takes multiple appeals to gain approval from payers for ECD treatments in the US. In order to lessen the burden of this on the medical provider staff, example appeal letters and supporting journal articles have been assembled. The following information will provide guidance on the appeal process to achieve treatment coverage for your ECD patient.  For patients living outside the US, the process may be different to gain approval for a particular treatment.  However, the same information may still be helpful in getting approval for a particular treatment.

Working with insurance companies on a case-by-case basis requires much time and effort. The drugs that are used to treat Erdheim-Chester Disease are certainly no exception. Some of the off-label treatments for ECD include:  Anakinra, dabrafenib, trametinib, cobimetinib, cladribine, and methotrexate. Most insurance companies have a list of drugs that require pre-authorization, and these drugs are typically on these lists. These drugs are costly and difficult for a patient to cover alone.

支付方通常采用的评估流程是：由护士或药剂师审核申请，确认所申请的药物是否用于美国食品药品监督管理局（FDA）批准的适应症。如果该药物未出现在FDA批准的清单中，申请将自动被驳回。这会使申请进入申诉阶段，通常由医疗总监进行进一步评估。 此阶段的处理方式差异极大，但此时的申请通常也会被驳回。如果该药物最终获得批准，有时可能需要进行多达四次上诉。当所有内部上诉途径均已用尽后，患者有权申请外部审查。这一过程往往给患者带来巨大压力，同时也耗费医生和工作人员大量时间。.

为支持这些工作，我们针对那些常被开具但保险理赔被拒的药物，整理了一系列文章并起草了一封申诉信。 为协助医务人员向患者的保险公司申请治疗批准，现已提供以下药物文章和申诉信的链接。其他医生在申请中使用这些表格已取得成功。这些信函可作为申诉的模板指南，而相关文章则通过医学事实和研究结果为申请提供支持。.

重要– 建议医生和工作人员在申请ECD治疗和监测时，针对某些影像学检查（尤其是PET扫描），使用ICD-10代码D76.3（即“其他组织细胞增生综合征”）和/或C96A（即“组织细胞肉瘤”）。.

如果您在此过程中需要更多帮助，或者希望提供反馈，请联系 ECDGA。.